The Food and Drug Administration (FDA) has accepted three New Drug Applications (NDAs) from Merck and Pfizer Inc., for drugs containing ertugliflozin, a new medication from a class of diabetes drugs known as SGLT2 inhibitors. The three NDAs include an ertugliflozin only treatment, a fixed-dose combination of ertugliflozin and the diabetes drug Januvia (sitagliptin), and a fixed-dose combination of ertugliflozin and the first-line diabetes drug metformin. The FDA is expected to review the medication in December 2017. Additionally, the European Medicines Agency (EMA) has also agreed to review three drug applications containing ertugliflozin. The applications are supported by studies comprised ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.